NCT04154670 is a Phase 1 clinical trial of MGTA-145 in Healthy, sponsored by Ensoma.

Who is sponsoring NCT04154670?

NCT04154670 is sponsored by Ensoma.

What drugs are being tested in NCT04154670?

Interventions in NCT04154670: MGTA-145.

What condition does NCT04154670 study?

NCT04154670 studies Healthy, Renal Insufficiency.

Is NCT04154670 still recruiting?

NCT04154670 is currently completed. Last updated 11 January 2024.

Last reviewed 2024-01-11 · How we verify

NCT04154670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

Completed Phase 1 Last updated 11 January 2024

What this trial tests

Phase 1 trial testing MGTA-145 in Healthy in 23 participants. Completed in 24 March 2020.

Timeline

7 November 2019

Primary endpoint
24 March 2020

24 March 2020

Quick facts

Lead sponsor	Ensoma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	7 November 2019
Primary completion	24 March 2020
Estimated completion	24 March 2020
Sites	2 locations across United States

Drugs / interventions tested

MGTA-145 — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →
Renal Insufficiency — all drugs for Renal Insufficiency →

Sponsor

Ensoma — full company profile →

Who can join

Adults 18 to 79, any sex, with Healthy or Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted in healthy subjects and in subjects with a mild or moderate decrease in GFR (subjects with renal impairment).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hematopoietic Stem Cell Mobilization: Current Collection Approaches, Stem Cell Heterogeneity, and a Proposed New Method for Stem Cell Transplant Conditioning.
Menendez-Gonzalez JB, Hoggatt J. · · 2021 · cited 11× · PMID 34661830 · DOI 10.1007/s12015-021-10272-1

Verify or expand the search:

Other trials of MGTA-145

Trials testing the same drug.

NCT05445128 — Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease · Phase 2 · terminated
NCT04762875 — MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies · Phase 2 · terminated
NCT04552743 — MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma · Phase 2 · completed
NCT03932864 — Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Sing · Phase 1 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Ensoma trials

Trials by the same sponsor.

NCT05445128 — Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease · Phase 2 · terminated
NCT04762875 — MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies · Phase 2 · terminated
NCT03932864 — Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Sing · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04154670 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ensoma
Last refreshed: 11 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04154670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing